Factors associated with immunotherapy selection in patients with advanced melanoma

Richard W Joseph, Alicia C. Shillington, Cynthia Macahilig, Scott J. Diede, Vaidehi Dave, Qing Harshaw, Frank Xiaoqing Liu

Research output: Contribution to journalArticle

2 Scopus citations


AIM: To explore factors associated with pembrolizumab (PEMBRO) versus ipilimumab + nivolumab (IPI+NIVO) selection in advanced melanoma. MATERIALS & METHODS:  Total of 12 academic and satellite clinics contributed to this study. Descriptive and logistic regression analyses were conducted to explore associations between clinical characteristics and treatment choice.  Results: Total of 400 patients were included: 200 PEMBRO and 200 IPI+NIVO. Patients were significantly more likely to receive PEMBRO versus IPI+NIVO if they had poorer Eastern Cooperative Oncology Group score, 2-4 versus 0-1 (odds ratio [OR]: 6.6; 95% CI: 3.0-14.7), if they were PD-L1 positive (OR: 4.5; 95% CI: 1.9-10.4) or had BRAF wild-type tumor (OR: 2.2; 95% CI: 1.4-3.6). CONCLUSION: Patient factors are significantly associated with treatment selection in advanced melanoma. Outcomes comparisons should take this into consideration.

Original languageEnglish (US)
Pages (from-to)1361-1369
Number of pages9
Issue number16
StatePublished - Nov 1 2018



  • advanced melanoma
  • immunotherapy
  • ipilimumab
  • nivolumab
  • pembrolizumab
  • real-world study
  • treatment selection

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Joseph, R. W., Shillington, A. C., Macahilig, C., Diede, S. J., Dave, V., Harshaw, Q., & Liu, F. X. (2018). Factors associated with immunotherapy selection in patients with advanced melanoma. Immunotherapy, 10(16), 1361-1369. https://doi.org/10.2217/imt-2018-0150